Compare Five Below Inc (FIVE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Five Below Inc trades at $209.72 (market cap $11.25B), while State Street SPDR S&P Biotech ETF trades at $149.99 (market cap $10.08B). The key difference: Five Below Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FIVE | XBI | |
|---|---|---|
Market Cap | $11.25B | $10.08B |
Volume | 986,546 | 9,534,635 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $262.72 | $169.55 |
52-Week Low | $138.49 | $104.99 |
Typical Hold Time | 46 Days | 37 Days |
Enterprise Value | $12.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $209.56, down 0.17% on the day, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 40.26% gross margins and 28.25% ROE, though net margins declined to 6.54% in 2025. Recent earnings beats and a raised 2026 outlook highlight growth momentum, supported by store expansion and digital initiatives. Cash flow improved significantly in 2025 with $152M net inflow after two years of negative flows.
The stock offers substantial upside to the $298.44 consensus target, with 60% analyst buy ratings and no sell recommendations. Key risks include premium valuation (P/E 18.32) and execution pressure amid consumer spending concerns. Growth catalysts include the $600M buyback and store revamp strategy, though technical resistance near $212 may limit near-term gains.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
